Strongbridge Biopharma (NASDAQ: SBBP) and Acura Pharmaceuticals (OTCMKTS:ACUR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.
This table compares Strongbridge Biopharma and Acura Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and target prices for Strongbridge Biopharma and Acura Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Strongbridge Biopharma presently has a consensus price target of $14.67, suggesting a potential upside of 94.26%. Acura Pharmaceuticals has a consensus price target of $0.55, suggesting a potential upside of 22.22%. Given Strongbridge Biopharma’s higher possible upside, equities analysts plainly believe Strongbridge Biopharma is more favorable than Acura Pharmaceuticals.
Volatility & Risk
Strongbridge Biopharma has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Acura Pharmaceuticals has a beta of 2.56, meaning that its share price is 156% more volatile than the S&P 500.
Institutional and Insider Ownership
67.7% of Strongbridge Biopharma shares are owned by institutional investors. Comparatively, 9.4% of Acura Pharmaceuticals shares are owned by institutional investors. 4.2% of Strongbridge Biopharma shares are owned by insiders. Comparatively, 5.6% of Acura Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Strongbridge Biopharma and Acura Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Strongbridge Biopharma||$7.05 million||48.76||-$113.48 million||($1.45)||-5.21|
|Acura Pharmaceuticals||$4.46 million||2.10||-$7.38 million||N/A||N/A|
Acura Pharmaceuticals has lower revenue, but higher earnings than Strongbridge Biopharma.
Acura Pharmaceuticals beats Strongbridge Biopharma on 6 of the 11 factors compared between the two stocks.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that is used for treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
Acura Pharmaceuticals Company Profile
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide. The company was founded in 1935 and is based in Palatine, Illinois.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.